人工智能直接从肝细胞癌组织学预测免疫和炎症基因特征
本研究利用人工智能分析肝细胞癌全切片数字组织学图像,开发并验证了能预测6种免疫基因特征激活的模型。CLAM模型在发现队列中预测免疫基因特征上调肿瘤的最佳AUC为0.78至0.91,在验证数据集中AUC为0.81至0.92。高度预测组织区域的病理分析显示淋巴细胞、浆细胞和中性粒细胞富集。
要点
- CLAM模型在发现队列中预测免疫基因特征上调肿瘤的最佳AUC为0.78至0.91。
- 不同模型在验证数据集中泛化良好,AUC为0.81至0.92。
- 高度预测组织区域病理分析显示淋巴细胞、浆细胞和中性粒细胞富集。
核心结论
- 研究开发并验证了基于人工智能的病理模型,能够预测多种免疫和炎症基因特征的激活。
- 该方法还提供了影响模型预测的形态学特征的见解。
- 这项概念验证研究表明,基于人工智能的病理学可能代表一种新型生物标志物,将有助于把肝细胞癌的生物学知识转化为临床实践。
研究设计与样本
- 人工智能模型在2个不同的接受手术切除的肝细胞癌患者系列中进行训练和验证。
- 基因表达通过RNA测序或NanoString技术检测。
- 研究了三种深度学习方法:基于图像块的方法、经典多实例学习和CLAM。
- 对所有基因特征进行了最具预测性组织区域的病理学复查。
主要发现
- CLAM模型在发现系列中表现出最佳的整体性能。
- CLAM模型预测免疫基因特征上调肿瘤的最佳折的受试者工作特征曲线下面积(AUC)范围为0.78至0.91。
- 不同模型在验证数据集中泛化良好,AUC范围为0.81至0.92。
- 高度预测组织区域的病理分析显示淋巴细胞、浆细胞和中性粒细胞富集。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with hepatocellular carcinoma (HCC) displaying overexpression of immune gene signatures are likely to be more sensitive to immunotherapy, however, the use of such signatures in clinical settings remains challenging. We thus aimed, using artificial intelligence (AI) on whole-slide digital histological images, to develop models able to predict the activation of 6 immune gene signatures. METHODS: AI models were trained and validated in 2 different series of patients with HCC treated by surgical resection. Gene expression was investigated using RNA sequencing or NanoString technology. Three deep learning approaches were investigated: patch-based, classic MIL and CLAM. Pathological reviewing of the most predictive tissue areas was performed for all gene signatures. RESULTS: The CLAM model showed the best overall performance in the discovery series. Its best-fold areas under the receiver operating characteristic curves (AUCs) for the prediction of tumors with upregulation of the immune gene signatures ranged from 0.78 to 0.91. The different models generalized well in the validation dataset with AUCs ranging from 0.81 to 0.92. Pathological analysis of highly predictive tissue areas showed enrichment in lymphocytes, plasma cells, and neutrophils. CONCLUSION: We have developed and validated AI-based pathology models able to predict the activation of several immune and inflammatory gene signatures. Our approach also provides insights into the morphological features that impact the model predictions. This proof-of-concept study shows that AI-based pathology could represent a novel type of biomarker that will ease the translation of our biological knowledge of HCC into clinical practice. LAY SUMMARY: Immune and inflammatory gene signatures may be associated with increased sensitivity to immunotherapy in patients with advanced hepatocellular carcinoma. In the present study, the use of artificial intelligence-based pathology enabled us to predict the activation of these signatures directly from histology.
引用
- Zeng Q, Klein C, Caruso S, et al. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol. 2022. PMID: 35143898. doi:10.1016/j.jhep.2022.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。